DDrare: Database of Drug Development for Rare Diseases

Searched query = "Huge arteriovenous malformation with cervicofacial or limb lesion", "Huge arteriovenous malformation", "Arteriovenous malformation"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 68Ga-NEB; Bevacizumab; Bleomycin; Dexmedetomidine; Dexmedetomidine 1; Dexmedetomidine 2; Dexmedetomidine 3; Doxycycline; Ethanol; Heparin; Heparin Sodium; L04AA10; Lipiodol; Lipiodol® Ultra Fluid with surgical glues; Lovastatin; Mekinist; Minocycline; Other: normal saline; RAPAMUNE; Rapamune; SIROLIMUS; Sirolimus; Sirolimus 0,1% crème; Sirolimus 1mg/mL; Sufentanil; Thalidomide

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR1900021901	2019-03-20	2019-03-15	Efficacy and Safety of Thalidomide for the Treatment of Arteriovenous Malformations in Central Nervous System: Pilot Study	Efficacy and Safety of Thalidomide for the Treatment of Arteriovenous Malformations in Central Nervous System: Pilot Study	central nervous system arteriovenous malformations	Case series:Oral thalidomide;	Xuanwu Hospital, Capital Medical University	NULL	Completed			Both	Case series:30;		China
2	NCT00389935 (ClinicalTrials.gov)	October 2006	17/10/2006	Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding	Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding	Arteriovenous Malformation;Hereditary Hemorrhagic Telangiectasia;Hematochezia;Melena	Drug: Thalidomide	Northport Veterans Affairs Medical Center	Georgia Regents University;University of Massachusetts, Worcester	Completed	18 Years	N/A	Both	14	Phase 2	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

ChiCTR1900021901

2019-03-20

2019-03-15

Efficacy and Safety of Thalidomide for the Treatment of Arteriovenous Malformations in Central Nervous System: Pilot Study

central nervous system arteriovenous malformations

Case series:Oral thalidomide;

Xuanwu Hospital, Capital Medical University

NULL

Completed

Both

Case series:30;

China

NCT00389935
(ClinicalTrials.gov)

October 2006

17/10/2006

Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding

Arteriovenous Malformation;Hereditary Hemorrhagic Telangiectasia;Hematochezia;Melena

Drug: Thalidomide

Northport Veterans Affairs Medical Center

Georgia Regents University;University of Massachusetts, Worcester

Completed

18 Years

N/A

Both

Phase 2

United States